help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thiele, E. A.
Right arrow Articles by Eipper, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thiele, E. A.
Right arrow Articles by Eipper, B. A.

Endocrinology, Vol 125, 2279-2288, Copyright © 1989 by Endocrine Society


ARTICLES

Tissue-specific regulation of peptidyl-glycine alpha-amidating monooxygenase expression

EA Thiele, KL Marek and BA Eipper
Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Peptidyl-glycine alpha-amidating monooxygenase (PAM; EC 1.14.17.3) is present in a variety of tissues, where it plays a vital role in the processing of numerous peptide substrates, often conferring bioactivity. PAM is present in high amounts in heart atrial myocytes and the pituitary gland, where activity is present in both soluble and membrane forms. We used AtT-20 cells, a mouse corticotrope tumor cell line, and primary heart atrial cultures to establish the occurrence of tissue-specific regulation of PAM expression. In the AtT-20 cells, PAM expression is regulated in parallel with the source of its peptide substrate, pro-ACTH/endorphin. PAM mRNA levels are increased to 132 +/- 5% of control values by treatment with (Bu)2-cAMP and decreased to 55 +/- 7% of control values by treatment with dexamethasone. Treatment with (Bu)2cAMP decreases PAM specific activity in the AtT-20 cells to 68 +/- 4% of the control value, presumably due to secretion of enzyme from the cells; dexamethasone treatment decreases PAM specific activity to 57 +/- 1% of the control value. In contrast, in heart atrial cultures, dexamethasone stimulates PAM expression. In atrial cultures exposed to dexamethasone for 48 h, PAM mRNA and PAM specific activity are elevated to 230 +/- 50% and 220 +/- 20% of control values, respectively; secretion of PAM activity is increased to 230% of the control value. As for AtT-20 cells, treatment of atrial cultures with (Bu)2cAMP increases PAM mRNA levels. Thus, PAM expression is regulated in a tissue-specific manner by dexamethasone in the two tissues examined. In AtT-20 cells, time-course studies and studies with cycloheximide indicate that dexamethasone exerts its effects on PAM mRNA levels by an indirect mechanism involving protein synthesis.


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
F. Brenet, N. Dussault, J. Borch, G. Ferracci, C. Delfino, P. Roepstorff, R. Miquelis, and L. Ouafik
Mammalian Peptidylglycine {alpha}-Amidating Monooxygenase mRNA Expression Can Be Modulated by the La Autoantigen
Mol. Cell. Biol., September 1, 2005; 25(17): 7505 - 7521.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. El Meskini, R. E. Mains, and B. A. Eipper
Cell Type-Specific Metabolism of Peptidylglycine {alpha}-Amidating Monooxygenase in Anterior Pituitary
Endocrinology, August 1, 2000; 141(8): 3020 - 3034.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. D. Ciccotosto, T. A. Hand, R. E. Mains, and B. A. Eipper
Breeding Stock-Specific Variation in Peptidylglycine {alpha}-Amidating Monooxygenase Messenger Ribonucleic Acid Splicing in Rat Pituitary
Endocrinology, February 1, 2000; 141(2): 476 - 486.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. J. Driscoll, S. A. Mueller, B. A. Eipper, and G. P. Mueller
Differential Regulation of Peptide alpha -Amidation by Dexamethasone and Disulfiram
Mol. Pharmacol., June 1, 1999; 55(6): 1067 - 1076.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
T. O. Bruhn, J. M. M. Rondeel, and I. M. D. Jackson
Thyrotropin-Releasing Hormone Gene Expression in the Anterior Pituitary. IV. Evidence for Paracrine and Autocrine Regulation
Endocrinology, August 1, 1998; 139(8): 3416 - 3422.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Fraboulet, F. Boudouresque, C. Delfino, and L'H. Ouafik
Identification of a Novel cis-Element in the 3'-Untranslated Region of Mammalian Peptidylglycine {alpha}-Amidating Monooxygenase Messenger Ribonucleic Acid
Endocrinology, March 1, 1998; 139(3): 894 - 904.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. D. Oldham, C. Li, J. Feng, R. O. Scott, W. Z. Wang, A. B. Moore, P. R. Girard, J. Huang, R. B. Caldwell, R. W. Caldwell, et al.
Amidative peptide processing and vascular function
Am J Physiol Cell Physiol, December 1, 1997; 273(6): C1908 - C1914.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. El Meskini, C. Delfino, F. Boudouresque, M. Hery, C. Oliver, and L'H. Ouafik
Estrogen Regulation of Peptidylglycine {alpha}-Amidating Monooxygenase Expression in Anterior Pituitary Gland
Endocrinology, January 1, 1997; 138(1): 379 - 388.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society